Key facts
- This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
- 10 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2026, 16:05.
Jonathan Mark Hopper - 24 Feb 2026 Form 4 Insider Report for Vericel Corp (VCEL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VCEL
- Reported as of
- 24 Feb 2026
- Net transaction value
- -$75,177
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2026, 16:05:35 UTC
- Prior SEC filing
- 20 Feb 2026
- Next SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 26 Feb 2026.
Change
- Previous filing in this sequence was filed on 20 Feb 2026.
- Current net transaction value: -$75,177.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001626325
Primary reporting owner
Hopper Jonathan Mark
- Relationship
- Chief Medical Officer
- Address
- 64 SIDNEY STREET, CAMBRIDGE
- Signature
- /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
- Signature date
- 26 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +350
- Change %
- +0.49%
- Price
- Shares after
- 71,377
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +3,150
- Change %
- +4.4%
- Price
- $0.000000
- Shares after
- 74,527
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F3, F4
VCEL
transaction
Common Stock
Tax liability
- Transaction value
- $50,850
- Shares
- -1,335
- Change %
- -1.8%
- Price
- $38.09
- Shares after
- 73,192
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F3, F5
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,500
- Change %
- +2%
- Price
- Shares after
- 74,692
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F3, F6
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,500
- Change %
- +2%
- Price
- $0.000000
- Shares after
- 76,192
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F3, F7
VCEL
transaction
Common Stock
Tax liability
- Transaction value
- $24,327
- Shares
- -636
- Change %
- -0.83%
- Price
- $38.25
- Shares after
- 75,556
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VCEL
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- +350
- Change %
- +2.6%
- Price
- Shares after
- 13,650
- Date
- 24 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 350
- Exercise price
- Footnotes
- F2, F8, F9
VCEL
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- +3,150
- Change %
- +43%
- Price
- Shares after
- 10,500
- Date
- 24 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,150
- Exercise price
- Footnotes
- F4, F8, F9, F10
VCEL
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- +1,500
- Change %
- +25%
- Price
- Shares after
- 7,500
- Date
- 24 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500
- Exercise price
- Footnotes
- F6, F8, F9
VCEL
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- +1,500
- Change %
- +33%
- Price
- Shares after
- 6,000
- Date
- 24 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500
- Exercise price
- Footnotes
- F7, F8, F9, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
Footnote F2
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
Footnote F3
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Footnote F4
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
Footnote F5
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
Footnote F6
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
Footnote F7
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively.
Footnote F8
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
Footnote F9
No expiration date for this type of award.
Footnote F10
The Fair Market Value of the vested derivative securities is $38.09 per share.
Footnote F11
The Fair Market Value of the vested derivative securities is $38.25 per share.